These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

986 related items for PubMed ID: 23150952

  • 1. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 3. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A, Motro M, Fisman EZ.
    Cardiovasc Diabetol; 2005 Sep 16; 4():14. PubMed ID: 16168052
    [Abstract] [Full Text] [Related]

  • 4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Sep 16; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 5. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2010 Jun 15; 9():24. PubMed ID: 20550659
    [Abstract] [Full Text] [Related]

  • 6. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R.
    Vasc Health Risk Manag; 2013 Jun 15; 9():617-70. PubMed ID: 24174878
    [Abstract] [Full Text] [Related]

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Jun 15; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 8. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Cardiovasc Diabetol; 2006 Sep 26; 5():20. PubMed ID: 17002798
    [Abstract] [Full Text] [Related]

  • 9. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 26; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 10. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 26; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 11. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 12. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR.
    Expert Opin Pharmacother; 2015 Mar 08; 16(4):597-606. PubMed ID: 25674933
    [Abstract] [Full Text] [Related]

  • 13. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S, Masuda D, Matsuzawa Y.
    Curr Atheroscler Rep; 2020 Jan 23; 22(1):5. PubMed ID: 31974794
    [Abstract] [Full Text] [Related]

  • 14. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A.
    Cardiovasc Diabetol; 2019 Jun 17; 18(1):80. PubMed ID: 31208414
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun 17; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

  • 17. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M.
    Int J Mol Sci; 2018 Apr 14; 19(4):. PubMed ID: 29662003
    [Abstract] [Full Text] [Related]

  • 18. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
    Nikolic D, Castellino G, Banach M, Toth PP, Ivanova E, Orekhov AN, Montalto G, Rizzo M.
    Curr Pharm Des; 2017 Mar 26; 23(6):894-902. PubMed ID: 27719644
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
    Yin WH, Jen HL, Chen JW, Lin SJ, Young MS.
    Diabetes Metab; 2006 Jun 26; 32(3):229-35. PubMed ID: 16799399
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.